3 hours agoOxford vaccine also produces encouraging results for older people infected with COVID-19
Periskopi(6 years ago)
(6 years ago)Oxford's vaccine against the coronary is showing that there is a strong immune response to adults who are about 60 and 70 years old, raising hopes that they can protect the most endangered age groups. Researchers say the findings of Lancet's phase two, based on 560 adult volunteers and more [...]
Researchers say that the findings of Lancet's phase two, based on 560 adult volunteers and in good health, are <x0 encouraging>”, Kosovo reports.
They are also testing it if the vaccine prevents the development of coronary, of the third phase.
Early results from this important phase are expected to emerge in the coming weeks.
Three Pfizer vaccines - BioNTech, Sputnik and Moderna have already reported good preliminary data from the third phase evidence, with one suggesting that 94% of people over 65 could be protected by COVID-19.
Great Britain has already ordered 100 million doses of the Oxford vaccine produced by AstraZeneca, 40 million doses of Pfizer vaccine. - B NTech and five million of the Modern vaccine.
